Início › Câncer Endometrial › Tennessee › Nashville
Ensaios clínicos de Câncer Endometrial em Nashville, TN
38 estudos para Câncer Endometrial estão buscando participantes em locais em Nashville e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecrutandoFase 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin · a 17 mi de distância
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecrutandoFase 2
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of PHST001 in Advanced Solid Tumors
RecrutandoFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecrutandoFase 1
- Tennessee Oncology, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecrutandoFase 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RecrutandoFase 1
- SCRI Oncology Partners, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecrutandoFase 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecrutandoFase 2
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecrutandoFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
DESTINY-PANTUMOUR04
RecrutandoEstudo observacional
- Research Site, Nashville
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecrutandoFase 1
- Research Site, Nashville
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RecrutandoFase 2
- Research Site, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecrutandoFase 1/2
- Sarah Cannon Research Institue, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecrutandoFase 1
- Sarah Cannon - Tennessee Oncology, Nashville
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RecrutandoFase 1/2
- Sarah Cannon Nashville, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
RecrutandoFase 1/2
- GSK Investigational Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecrutandoFase 1
- Sarah Cannon Research Institute, Nashville
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
RecrutandoFase 1
- Sarah Cannon Research Institute, Nashville
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RecrutandoFase 1
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RecrutandoFase 1
- SCRI Oncology Partners - Nashville, Nashville
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RecrutandoFase 1
- SCRI Oncology Partners, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RecrutandoFase 1
- Normunity Investigational Site, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecrutandoFase 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RecrutandoFase 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecrutandoFase 1/2
- SCRI Oncology Partners, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecrutandoFase 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecrutandoFase 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecrutandoFase 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecrutandoFase 2
- SCRI Oncology Partners, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecrutandoFase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecrutandoFase 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
A Study of LY4175408 in Participants With Advanced Cancer
RecrutandoFase 1
- Sarah Cannon Research Institute, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecrutandoFase 1
- SCRI Oncology Partners, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecrutandoFase 1/2
- Sarah Cannon Research Institute, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RecrutandoFase 1/2
- Tennessee Oncology, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecrutandoFase 1/2
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Ensaios de Câncer Endometrial em outras cidades
- Houston, TX68 estudos
- New York City, NY52 estudos
- Boston, MA50 estudos
- Arlington, VA39 estudos
- Los Angeles, CA34 estudos
- St. Louis, MO29 estudos
- Philadelphia, PA28 estudos
- San Antonio, TX27 estudos
- Columbus, OH25 estudos
- Chicago, IL25 estudos
- Oklahoma City, OK25 estudos
- Queens, NY25 estudos
Outros estudos em Nashville
- Câncer de Pulmão de Não Pequenas Células97 estudos
- Câncer de Mama81 estudos
- Câncer Metastático70 estudos
- Câncer Colorretal69 estudos
- Câncer (todos os tipos)65 estudos
- Câncer de Ovário49 estudos
- Câncer de Próstata43 estudos
- Câncer de Pulmão40 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço39 estudos
- Câncer de Pâncreas39 estudos
- Melanoma33 estudos
- Mieloma Múltiplo32 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.